BMS's immunotherapy ipilimumab shows survival benefit in Phase III advanced melanoma trial
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's novel anti-CTLA-4 immunotherapy ipilimumab has improved overall survival by close to four months in a Phase III trial in previously treated melanoma, compared with an experimental therapeutic cancer vaccine (gp100) that has been extensively tested in the disease, data presented at the ASCO meeting in Chicago show.